X4 Pharmaceuticals, Inc. (XFOR)

Market Cap	104.26M
Revenue (ttm)	1.12M
Net Income (ttm)	-16.76M
Shares Out	170.55M
EPS (ttm)	-0.09
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,987,886
Open	0.590
Previous Close	0.607
Day's Range	0.573 - 0.680
52-Week Range	0.261 - 1.600
Beta	0.34
Analysts	Strong Buy
Price Target	3.50 (+472.55%)
Earnings Date	Nov 13, 2024

About XFOR

X4 Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutrop...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 93
• Stock Exchange: NASDAQ
• Ticker Symbol: XFOR
• Website: https://www.x4pharma.com

Analyst Forecast

According to 3 analysts, the average rating for XFOR stock is "Strong Buy." The 12-month stock price forecast is $3.5, which is an increase of 472.55% from the latest price.

Price Target

$3.5

(472.55% upside)

Analyst Consensus: Strong Buy